Drugs /

xelox regimen

Back to Drugs List

Overview

NCI Definition [1]:
A regimen consisting of capecitabine and oxaliplatin used for the treatment of advanced stage colorectal cancer. This regimen differs from a similar regimen, CAPOX, with regards to the dosing schedule for oxaliplatin.

Clinical Trials

View Clinical Trials for xelox regimen

Xelox regimen has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating xelox regimen, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).

ERBB2 Amplification, HER2 Deficient Expression, and HER2 Equivocal are the most frequent biomarker inclusion criteria for xelox regimen clinical trials.

Adenocarcinoma of the gastroesophageal junction, biliary tract carcinoma, and colorectal carcinoma are the most common diseases being investigated in xelox regimen clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Xelox Regimen
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating xelox regimen and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
xelox, xeloda/oxaliplatin, xeloda-oxaliplatin regimen, capeox, capecitabine/oxaliplatin
NCIT ID [1]:
C63597

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.